Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres

Abstract

PurposeTo utilize voxel-based dosimetry following radiation segmentectomy (RS) to understand microsphere distribution and validate current literature regarding radiologic and pathologic outcomes. Materials and MethodsA retrospective, single-center analysis of patients with solitary hepatocellular carcinoma (N = 56) treated with yttrium-90 (90Y) RS with glass microspheres (Therasphere; Boston Scientific, Marlborough, Massachusetts) from 2020 to 2022 was performed. Posttreatment voxel-based dosimetry was evaluated using Mirada DBx Build 1.2.0 Simplicit90Y software (Boston Scientific) and utilized to calculate sphere concentration to tumor as well as D70 (minimum dose to 70% total tumor volume), D90, and D99. Time to progression (TTP), treatment response, and adverse events were studied. ResultsFifty-six solitary tumors were analyzed with a median tumor diameter of 3.4 cm (range, 1.2–6.8 cm) and median tumor absorbed dose of 732 Gy (range, 252–1,776 Gy). Median sphere activity (SA) at the time of delivery was 1,446 Bq (range, 417–2,621 Bq). Median tumor sphere concentration was 12,868 spheres/mL (range, 2,655–37,183 spheres/mL). Sphere concentration into tumor and normal tissue was inversely correlated with perfused treatment volume (R2 = 0.21 and R2 = 0.39, respectively). Of the 51 tumors with posttreatment imaging, objective response was noted in 49 patients (96%) and complete response in 42 patients (82%). The median TTP was not reached with a 2-year progression rate of 11%. Fifteen patients underwent liver transplant. Median tumor necrosis was 99% (range, 80%–100%). Lower tumor volumes and higher D99 were associated with complete pathologic necrosis (P < .001 and P = .022, respectively). ConclusionsVoxel-based dosimetry following 90Y radioembolization can be utilized to account for sphere deposition and distribution into tumor. Ablative RS with high SA yields durable radiologic and pathologic outcomes.